基于cGAS-STING信号通路探讨脑震宁含药血清对LPS诱导HT22细胞炎症的影响OA
Exploring the effect of Naozhenning(脑震宁)-containing serum on inflammation in LPS-induced HT22 cells based on the cGAS-STING signaling pathway
目的 探讨脑震宁含药血清对脂多糖(lipopolysaccharides,LPS)诱导HT22细胞炎症反应的调控作用,阐明其经cGAS-STING信号通路的作用机制.方法 先以CCK-8法确定LPS及脑震宁含药血清对HT22细胞的最佳作用浓度与时间,随后分组处理.空白组常规培养;LPS组用含LPS培养基诱导炎症;含药血清组在含LPS培养基中加入含药血清;抑制剂组先以STING抑制剂SN-011预处理,再用含LPS培养基培养;含药血清+抑制剂组先经SN-011预处理,再用含LPS培养基并加入含药血清.联合CCK-8与EDU法评估细胞增殖能力;用一氧化氮检测法明确神经元炎症状态;免疫荧光法测TNF-α阳性细胞率;ELISA法定量白细胞介素-18(interleukin-18,IL-18)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、干扰素-γ(interferon-γ,IFN-γ)炎症因子;Western blot 法测细胞环磷酸鸟苷-腺苷合成酶(cycliccyclic GMP-AMP synthase,cGAS)、干扰素基因刺激蛋白(stimulator of interferon genes,STING)、磷酸化干扰素基因刺激蛋白(phosphorylated-STING,p-STING)、干扰素调节因子3(interferon regulatory factor 3,IRF3)蛋 白 表 达;qRT-PCR检测细胞线粒体DNA(mitochondrial DNA,mtDNA)的拷贝数.结果 与空白组比较,LPS组HT22细胞相对增殖率显著降低,一氧化氮含量、荧光阳性率、IL-18、TNF-α、IFN-γ含量显著升高,cGAS、STING、p-STING、IRF3蛋白表达及mtDNA的拷贝数均显著增加(P<0.01);与LPS组比较,含药血清组、抑制剂组、含药血清+抑制剂组HT22细胞相对增殖率显著升高,荧光阳性率、IL-18、TNF-α、IFN-γ含量显著降低,cGAS、STING、IRF3蛋白表达及mtDNA的拷贝数均显著降低(P<0.05或P<0.01).结论 脑震宁含药血清可改善LPS诱导的HT22细胞炎症状况,推测其作用机制是由cGAS-STING信号通路介导的.
Objective To investigate the regulatory effect of Naozhenning(脑震宁,NZN)-containing serum on lipopolysaccharide(LPS)-induced inflammatory response in HT22 cells,and to clarify its mechanism of action through the cyclic GMP-AMP synthase(cGAS)-stimulator of interferon genes(STING)signaling pathway.Methods First,the optimal working concentrations and durations of LPS and NZN serum on HT22 cells were determined by the CCK-8 assay,followed by grouped treatment.The blank group was cultured routinely;the LPS group was induced for inflammation with LPS-containing medium;the NZN serum group was treated with LPS-containing medium supplemented with NZN serum;the inhibitor group was preconditioned with the STING inhibitor SN-011 prior to cul‑ture in LPS-containing medium;the NZN serum+inhibitor group was first preconditioned with SN-011,then cultured in LPS-containing medium supplemented with NZN serum.Cell proliferation capacity was evaluated by combining the CCK-8 and EdU assays;neuronal inflammatory status was determined using the nitric oxide(NO)detection assay;the positive cell rate of tumor necrosis factor-α(TNF-α)was measured by immunofluorescence staining;inflammatory factors including interleukin-18(IL-18),TNF-α,and inter‑feron-γ(IFN-γ)were quantified via enzyme-linked immunosorbent assay(ELISA);the protein expressions of cGAS,STING,phosphorylated-STING(p-STING),and interferon regulatory factor 3(IRF3)in cells were detected by Western blot(WB);The copy number of mitochondrial DNA(mtDNA)in cells was detected using quantitative real-time polymerase chain reaction(qRT-PCR).Results Compared with the blank group,the relative proliferation rate of HT22 cells in the LPS group was significantly decreased,the NO content,fluorescence-positive rate,and levels of IL-18,TNF-α,and IFN-γ were significantly increased,and the protein expres‑sions of cGAS,STING,p-STING,and IRF3 as well as the copy number of mtDNA were all significantly upregulated(P<0.01).Com‑pared with the LPS group,the relative proliferation rate of HT22 cells in the NZN serum group,inhibitor group,and NZN serum+inhibitor group was significantly increased,the fluorescence-positive rate and levels of IL-18,TNF-α,and IFN-γ were significantly decreased,and the protein expressions of cGAS,STING,and IRF3 as well as the copy number of mtDNA were all significantly down‑regulated(P<0.05 or P<0.01).Conclusion NZN serum can ameliorate the inflammatory status of HT22 cells induced by LPS,and its mechanism of action is presumably mediated by the cGAS-STING signaling pathway.
张唯依;李难;王心如;徐树;赵乐;高丽;王永辉
山西中医药大学基础医学院,山西 晋中 030619山西中医药大学基础医学院,山西 晋中 030619山西中医药大学基础医学院,山西 晋中 030619山西中医药大学基础医学院,山西 晋中 030619山西中医药大学基础医学院,山西 晋中 030619山西中医药大学基础医学院,山西 晋中 030619山西中医药大学基础医学院,山西 晋中 030619
医药卫生
HT22细胞脂多糖炎症反应cGAS-STING信号通路脑震宁含药血清
HT22 cellsLPSInflammatory responsecGAS-STING signaling pathwayNaozhenning(脑震宁)-containing serum
《时珍国医国药》 2026 (19)
3642-3649,8
国家自然科学基金(82104972)山西省基础研究计划资助项目(202403021211146)山西省中医药管理局科研课题(2024ZYYB041)山西省中医药管理局重点研究室项目-方药配伍及功用重点研究室项目(zyyyjs2024023)山西省教育厅研究生教育创新计划项目-中医方剂学优秀研究生导师团队项目(2025TD21)山西中医药大学科技创新能力培育计划(2023PY-YS-03)
评论